RTW Investments LP Makes New Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

RTW Investments LP bought a new position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the third quarter, HoldingsChannel reports. The fund bought 1,850,648 shares of the company’s stock, valued at approximately $45,359,000. RTW Investments LP owned approximately 1.53% of Oruka Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. The Manufacturers Life Insurance Company bought a new stake in shares of Oruka Therapeutics during the third quarter worth $1,037,000. Janus Henderson Group PLC bought a new stake in shares of Oruka Therapeutics during the third quarter worth $5,840,000. Redmile Group LLC bought a new stake in shares of Oruka Therapeutics during the third quarter worth $10,091,000. Point72 Asset Management L.P. bought a new stake in shares of Oruka Therapeutics in the third quarter worth $11,822,000. Finally, Great Point Partners LLC bought a new stake in shares of Oruka Therapeutics in the third quarter worth $12,614,000. Institutional investors own 56.44% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Leerink Partnrs raised shares of Oruka Therapeutics to a “strong-buy” rating in a research note on Tuesday, September 17th. TD Cowen assumed coverage on shares of Oruka Therapeutics in a research note on Monday, September 16th. They issued a “buy” rating on the stock. Stifel Nicolaus assumed coverage on shares of Oruka Therapeutics in a research note on Friday, October 11th. They issued a “buy” rating and a $49.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research note on Monday, November 25th. Finally, Jefferies Financial Group assumed coverage on shares of Oruka Therapeutics in a research note on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective on the stock. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $43.17.

Oruka Therapeutics Trading Up 0.7 %

ORKA stock opened at $20.97 on Thursday. Oruka Therapeutics, Inc. has a 12-month low of $18.20 and a 12-month high of $53.88. The firm has a fifty day moving average price of $25.41.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.